CN102559828A - Method for preparing astragaloside IV by converting total saponins of astragalus by microorganisms - Google Patents
Method for preparing astragaloside IV by converting total saponins of astragalus by microorganisms Download PDFInfo
- Publication number
- CN102559828A CN102559828A CN2010106152654A CN201010615265A CN102559828A CN 102559828 A CN102559828 A CN 102559828A CN 2010106152654 A CN2010106152654 A CN 2010106152654A CN 201010615265 A CN201010615265 A CN 201010615265A CN 102559828 A CN102559828 A CN 102559828A
- Authority
- CN
- China
- Prior art keywords
- astragaloside
- total saponins
- cyclosiversioside
- radix astragali
- astragalus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a method for preparing astragaloside IV by converting total saponins of astragalus by microorganisms, which comprises the following steps of: preparing bacteria, mould and yeast into bacterium suspension or spore suspension and inoculating the bacterium suspension or the spore suspension into a seed culture medium to form seed solution; then inoculating the seed solution into a fermentation medium to carry out culturing; after the seed solution grows well, adding the total saponins of astragalus to carry out conversion; carrying out scanning and analysis by a TLC (Thin Layer Chromatography) to convert other astragaloside into the astragaloside IV, so that the amount of the astragaloside IV is improved by over four times; and extracting the conversion solution by an organic solvent and separating and purifying the conversion solution by macroporous resin to obtain a pure product of the astragaloside IV. According to the method disclosed by the invention, the defects of damage to the saponins, serious pollution, poor purposiveness and the like in the process of hydrolyzing the total saponins of astragalus by a chemical method can be overcome and the problem of enzyme instability in the process of hydrolyzing the total saponins of astragalus by an enzyme method can be solved. The method has the advantages of no pollution, strong specificity and high conversion rate. The purity of the prepared astragaloside IV can reach over 99.9 percent.
Description
Technical field
The present invention relates to the method that a kind of microbial transformation prepares Cyclosiversioside F; Especially a kind of utilization contains ethanoyl and the glycosyl in the microbial hydrolytic Radix Astragali total saponins of deacetylase and Glycosylase, prepares the method for Cyclosiversioside F with the microbial transformation Radix Astragali total saponins that improves Astragaloside content.
Background technology
The Radix Astragali (Radix Astragali) is one of conventional Chinese medicine, is the leguminous plants Radix Astragali
Astragalus membranaceus(Fischer) Bunge and Radix Astagali
A. membranaceus(Fisch.) Bunge var.
Mongholicus(Bunge) dry root of P. K. Hsiao.(the Astragalosides IV is from the Radix Astragali, to separate a kind of saponins compound with multiple pharmacologically active that obtains ASI) to Cyclosiversioside F, is the index components of formulation of astragalus root quality evalution.Research has shown that Cyclosiversioside F all has pharmacological action widely in cardiovascular, immune, neural, digestion, uropoiesis, circulation and endocrine system etc., it is reported, Cyclosiversioside F can alleviate the hemato encephalic barrier perviousness increase that cerebral ischemia re-pouring causes; Ischemic brain injury had provide protection; Through regulating the expression performance antitumour activity of oncogene; Diabetic mice had hypoglycemic activity; Has strong anti-hepatitis B virus activities; Can effectively suppress or reverse the hepatic fibrosis of PS inductive mouse model; Its Chinese medicine preparation is developed to the treatment that myocardial protective agent is used for coronary heart disease and angina pectoris.But practice shows that Cyclosiversioside F content in the Radix Astragali is extremely low, and receives the place of production and seasonal effect bigger, generally is about 0.04%, and extraction separation is difficult.
(Astragalosides is the main effective constituent of the Radix Astragali AST) to Radix Astragali total saponins, accounts for the 2-3% of Radix Astragali dry weight.AST is a series of ring A Er front yard alkane type triterpenoid glycosides, its chemical structure such as figure below:
| ? | R1 | R2 | R3 |
| astragaloside IV | β-D-xylp | β-D-glcp | H |
| astragaloside I | β-D-xylp(2’3’-di-OAc) | β-D-glcp | H |
| astragaloside II | β-D-xylp(2’-OAc) | β-D-glcp | H |
| astragaloside VI | β-D-xylp-2’-β-D-glcp | β-D-glcp | H |
| astragaloside VII | β-D-xylp | β-D-glcp | β-D-glcp |
| Acetylastragaloside I | β-D-xylp(2’3’4'-tri-OAc) | β-D-glcp | H |
| isoastragaloside I | β-D-xylp(2'4'-di-OAc) | β-D-glcp | H |
| isoastragaloside II | β-D-xylp(3’-OAc) | β-D-glcp | H |
| agroastragaloside III | β-D-xylp(2’3’-di-OAc) | β-D-glcp | H |
| agroastragaloside IV | β-D-xylp(2’-OAc) | β-D-glcp | β-D-glcp |
| Cycloglobiceposide A | β-D-xylp(2’-OAc) | β-D-glcp(6’-OAc) | H |
Different Radix Astragali saponin structural difference mainly are 3-, the glycosyl kind of 6-and 25-position and quantity different, and Cyclosiversioside F i.e. wherein Radix Astragali saponin IV.Analyze from structure that unnecessary ethanoyl is removed in other Radix Astragali saponin hydrolysis or glycosyl all can be converted into Cyclosiversioside F.Main at present chemical method and the enzyme process of adopting is hydrolyzed to improve the content of Cyclosiversioside F to Radix Astragali total saponins, increases the extraction yield that from Chinese medicinal materials, extracts Cyclosiversioside F.
The content that how to improve Cyclosiversioside F is just causing relevant investigator's concern.
Summary of the invention
The objective of the invention is low, the separation and Extraction difficult technologies problem of Astragaloside content that exists in the prior art for solving; A kind of method for preparing Cyclosiversioside F through the microbial transformation Radix Astragali total saponins is provided; Especially utilize that other saponin(es are Cyclosiversioside F in the microbial transformation Radix Astragali total saponins, and from microbial fermentation solution the method for separation and purification Cyclosiversioside F.
The inventive method can improve Astragaloside content, for solving the source of Cyclosiversioside F, further develops Chinese medicine astragalus and lays the foundation.
Particularly, of the present inventionly prepare the method for Cyclosiversioside F, it is characterized in that it comprises step through the microbial transformation Radix Astragali total saponins:
Microbial strains is processed bacteria suspension or spore suspension; Be inoculated in the seed culture medium, 28 ℃, 220 rpm are cultivated 24 ~ 48 h and are promptly got seed liquor, seed liquor are inoculated in the fermention medium again; 28 ℃, 220 rpm are cultivated 24 ~ 48 h; Drop into Radix Astragali total saponins, the same terms transforms 48 ~ 96 h down, gets conversion fluid; Other Radix Astragali saponins of TLC scanning analysis are converted into Cyclosiversioside F, make the amount of Cyclosiversioside F improve more than 3 times.
Among the present invention; The conversion fluid that obtains; Can pass through organic solvent extraction and macroporous resin separation and purification Cyclosiversioside F, optimum means of purification is to adopt alcohol immersion earlier, uses n-butanol extraction again; Gained medicinal extract adopts the separation and purification of D101 macroporous resin again, behind ethyl acetate extraction, obtains purity astragaloside.In the embodiments of the invention, with 95% industrial alcohol soaked overnight, thalline and deposition are removed in centrifuging with above-mentioned fermented liquid, and rotary evaporation is to there being ethanol flavor, with twice of n-butanol extraction.Merge organic layer, revolve driedly, propyl carbinol reclaims.Gained medicinal extract redissolves with methyl alcohol, filters, and removes deposition.After filtrating is revolved and done,, at first remove sugar with zero(ppm) water prewashing with the separation and purification of D101 macroporous resin; Use a large amount of pigments of 2%KOH aqueous solution flush away again, use 19% ethanol, 23.75% ethanol, 47.5% ethanol and 57% ethanol elution then successively, TLC follows the tracks of detection; Merge and contain Cyclosiversioside F component and rotary evaporation, to there not being ethanol, remaining liq with ethyl acetate extraction once; Revolving behind the ETHYLE ACETATE remaining in the solid carbon dioxide layer is that the adularescent deposition is separated out, centrifugal 10 min of 10000 r/min, purity astragaloside; The recovery reaches more than 82%, and the Cyclosiversioside F chromatographic purity reaches 99.9%.
Among the present invention, described mikrobe is selected from bacterium, mould or yeast; Preferred absidia corymbifera in the embodiments of the invention (
Absidia corymbifera, available from the Shanghai City Industry Wei Biological Research Institute).
Among the present invention, described microbial transformation Cyclosiversioside F mainly contains ethanoyl and glycosyl in the microbial hydrolytic Radix Astragali total saponins of deacetylase and Glycosylase through utilization, improves Astragaloside content.
Among the present invention; Described Radix Astragali total saponins, its composition comprise all or part of Radix Astragali saponin monomer, like astragaloside I, II, VI, VII; Isoastragaloside I, II; The acetylastragaloside I, agroastragaloside III, IV, Cycloglobiceposide A etc.
Characteristics of the present invention are using microbe method for transformation; Other Radix Astragali saponins in the Radix Astragali total saponins are converted into Cyclosiversioside F; In the described microbial transformation; Utilize the substrate for enzymatic activity that produces in the microbial metabolism to carry out chemical reaction, because of its zone and stereoselectivity by force, can carry out the multistep enzymatic reaction simultaneously, reaction conditions is gentle, easy and simple to handle, cost is lower, the few industrial production that is suitable for of public hazards.Present method can overcome shortcomings such as chemical method hydrolysis for astragalus total saponins exists saponin(e is destroyed reaches, seriously polluted, purpose difference, and enzyme instability problem in the enzymatic hydrolysis Radix Astragali total saponins process.Have advantage pollution-free, that specificity is strong, transformation efficiency is high, the Cyclosiversioside F purity of preparation can reach more than 99.9%.
The present invention is in order to check the practicality of prepared Cyclosiversioside F, and adopting ethanol and Ucar 35 as non-aqueous solvent and solubility promoter described Cyclosiversioside F to be processed 1 mg/mL specification is the astragaloside injection of 2 mL.
Preferred ingredient is in the described injection liquid: as non-aqueous solvent and solubility promoter, Cyclosiversioside F 1 g, ethanol 200 mL, Ucar 35 200 mL, glucose 100 g, supply water for injection to 1000 mL by ethanol and Ucar 35.
The Cyclosiversioside F that the present invention makes can also be processed pharmaceutically acceptable preparation, like tablet, injection, suppository, external preparation etc.Can be used for the treatment of cardiovascular disorder, cerebrovascular disease, anticancer, antiviral, mellitus etc.
The invention provides the therepic use of described astragaloside injection at aspects such as cardiovascular and cerebrovascular diseases, antiviral and mellitus.Be particularly useful for the treatment of viral myocarditis.
Description of drawings
Fig. 1 is a fermented liquid TLC analysis among the present invention,
Wherein, the 1st, Radix Astragali total saponins, the 2nd, fermented liquid, the 3rd, contrast (bacterium liquid does not feed intake), the 4th, Cyclosiversioside F standard substance;
Fig. 2 is each step TLC analysis of Cyclosiversioside F separation and purification among the present invention,
Wherein, the 1st, the raw material Radix Astragali total saponins, the 2nd, the fermented liquid n-butanol extract, the 3rd, after macroporous resin separates, the 4th, the purity astragaloside that obtains, the 5th, Cyclosiversioside F standard substance;
Fig. 3 is each step HPLC chromatographic purity analysis of Cyclosiversioside F separation and purification among the present invention,
Wherein, A is n-butanol extract (chromatographic purity 35.9%), and B is that the D101 macroporous resin separates (chromatographic purity 61.98%), and C is purity astragaloside (chromatographic purity 99.9%).
Embodiment
Embodiment 1: utilize
Absidia corymbiferaTransform Radix Astragali total saponins and prepare Cyclosiversioside F
Two absidia corymbiferas (
Absidia corymbifera) test tube slant; Add 50 mL sterilized waters and process spore suspension, be inoculated in 250 mL that (every bottle 1 mL) be equipped with 50 mL liquid nutrient mediums and shake in the bottle, liquid nutrient medium is that (200 g yams add water 1 L to potato culture; Boil half a hour; Remove by filter residue, add 20 g glucose, natural pH in the filtrating).28 ℃, 220 rpm cultivate 24 h, get seed liquor.250 mL seed liquor are inoculated in the 5 L fermentation flasks that 1 L aforesaid liquid substratum is housed, and 28 ℃, 220 rpm cultivate 24 h, drop into bullion Radix Astragali total saponins (concentration that feeds intake 10 g/L), and the same terms transforms 72 h down.Fermented liquid TLC analytical results is seen Fig. 1,
Absidia corymbiferaCan other Radix Astragali saponins in the Radix Astragali total saponins be converted into Cyclosiversioside F.
Fermented liquid adds 1 L, 95% industrial alcohol soaked overnight, and thalline and some depositions are removed in centrifuging, and about rotary evaporation to 300 mL (no ethanol flavor), with 100 mL n-butanol extractions once, 50 mL propyl carbinols extract once again.Merge organic layer, revolve driedly, propyl carbinol reclaims.Gained medicinal extract redissolves with methyl alcohol, filters, and removes deposition, and filtrating is revolved dried subsequent use.Astragaloside content is 129.8 mg in the TLC scanning analysis filtrating, and it is 35.9% that HPLC analyzes chromatographic purity.Astragaloside content is 34.5 mg in the raw material Radix Astragali total saponins, and through after the microbial transformation, the amount of Cyclosiversioside F improves about 3 times.
Above-mentioned filtrating is with D101 macroporous resin (j20 * 250mm) separation and purification, and last appearance flow velocity 0.6ml/min at first removes sugar with 5 BV zero(ppm) water prewashing; Use a large amount of pigments of 5 BV 2%KOH aqueous solution flush awaies again, use 4BV 19% ethanol, 2BV 23.75% ethanol, 2BV 47.5% ethanol and 10BV 57% ethanol elution then successively, TLC follows the tracks of detection; Merge 47.5% cut and 57% cut rotary evaporation; To there not being ethanol, the about 340ml of remaining liq carries out thin layer scanning and gets Cyclosiversioside F 126.6 mg; The recovery 97.5%, chromatographic purity are 61.98%.
Aforesaid liquid with the 40ml ethyl acetate extraction once revolves ETHYLE ACETATE remaining in the solid carbon dioxide layer, and the adularescent deposition is separated out in the water, and centrifugal 10 min of 10000 r/min get Cyclosiversioside F white solid 107.6 mg, the recovery 82.9%, chromatographic purity 99.9%.
Each step TLC of separation and purification analyzes and sees Fig. 2, and Fig. 3 is seen in the analysis of HPLC chromatographic purity.
Embodiment 2: the astragaloside injection preparation
Prescription: Cyclosiversioside F 1.0 g
Ucar 35 200 mL
Glucose 100 g
Water for injection complements to 1000 mL
Preparing method: get the Cyclosiversioside F of recipe quantity, be dissolved under 40 ℃ in the mixing solutions of ethanol and Ucar 35 of recipe quantity, stir and also add part water for injection; The glucose that adds recipe quantity again; Supply water for injection to 1000 mL after the dissolving fully, 0.22 μ m strainer filters, embedding; Sterilization promptly gets 200 of 2 mL specification astragaloside injections.
1 experiment purpose adopts coxsackie B
3Virus (CVB
3) infect the mouse viral myocarditis model that causes, estimate of the therapeutic action of the astragaloside injection of the present invention's preparation to viral myocarditis, for treating viral myocarditis new drug development and clinical application experimental basis is provided.
2 experimental techniques are divided into two dose groups with Cyclosiversioside F, and 50 of Balb/c mouse are divided into 4 groups at random.Normal control group (5): do not give Cyclosiversioside F, virus inoculation is not only given the equivalent solvent; Virus control group (15): 0.1 mL CVB is inoculated in every abdominal cavity
3Virus liquid (TCID
50=10
-7.5, 10
5Doubly dilution); Administration group I---high dosage (15): the same method inoculation CVB
3Virus liquid, tail vein injection astragaloside injection 3 mg/kg on the same day, successive administration 7 d observe 15 d; Administration group II---low dosage (15): with administration group I method, tail vein injection astragaloside injection, dosage are 1 mg/kg.
Adopt the dosage of above-mentioned test to divide into groups, successive administration 7 d, observe 15 d after; The relatively M & M of each papova property myocarditis mouse, and dissection mouse is calculated cardiac index; Record heart change degree is done pathological section, and inverted phase contrast microscope is observed heart change.
3 experimental results
3.1 influence to the mice with viral myocarditis M & M
The mental status, diet, hair color and the death condition of each treated animal of observed and recorded during administration (raising).The result shows that two dose groups of medicine of the present invention all can significantly reduce by coxsackie B
3Virus (CVB
3) infect the M & M of the mice with viral myocarditis that causes, see table 1.
Table 1 medicine of the present invention is to the influence of mice with viral myocarditis M & M
| Group | Number of animals (only) | Sickness rate (routine number) | Mortality ratio (routine number) |
| The |
5 | 0（0） | 0（0） |
| The |
15 | 86.67%（13） | 33.33%（5） |
| High |
15 | 40.0%（6） | 6.67%（1） |
| Low |
15 | 53.33%(8) | 13.33%（2） |
Annotate: adopt chi square test, the administration group is organized relatively with virus.
3.2 influence to the mice with viral myocarditis cardiac index
Test the 15th day, mouse is all dissected.Take by weighing the mouse body weight before the dissection, take by weighing its cardiac weight after the dissection again, be calculated as follows cardiac index:
Cardiac index=heart weight/body weight
Animal by virus infection after, food ration reduces, body weight reduces, and therefore heart expands, fibrosis takes place and becomes weight, so can weigh the lesion degree of heart with cardiac index, cardiac index is big more, heart change is serious more.
The result shows that the high dose group of medicine of the present invention can significantly reduce by coxsackie B
3Virus (CVB
3) infect the cardiac index of the mice with viral myocarditis that causes, see table 2.
Table 2 medicine of the present invention is to the influence of mice with viral myocarditis cardiac index
| Group | Cardiac index (* 10 -3） |
| The normal control group | 4.66±0.72 |
| The virus control group | 6.53±1.21 |
| High dosage administration group | 5.47±0.83** |
| Low dosage administration group | 6.24±0.94 |
Annotate: the administration group compares * * P < 0.01 with the virus group.
3.3 influence to the apparent lesion degree of mice with viral myocarditis heart
Test the 15th day, mouse is all dissected.Write down observed heart change degree, mainly confirm, be divided into 0 from the size and the heart degree of expanding of patch shape pathology ,+, ++, +++, ++ ++ Pyatyi, lesion degree increases the weight of successively.
The result shows that two dose groups of medicine of the present invention all can significantly reduce by coxsackie B
3Virus (CVB
3) infect the apparent lesion degree of heart of the mice with viral myocarditis that causes, as shown in table 3.
Table 3 medicine of the present invention is to the influence of the apparent lesion degree of mice with viral myocarditis heart
| ? | 0 | + | ++ | +++ | ++++ | |
| Control group | ||||||
| 5 | 0 | 0 | 0 | 0 | 0 | |
| The virus group | 0 | 2 | 6 | 4 | 3 | 2.4 |
| High dosage administration group | 9 | 3 | 2 | 1 | 0 | 0.7** |
| Low |
4 | 3 | 7 | 1 | 0 | 1.3** |
Annotate: the administration group compares * * P < 0.01 with the virus group.
3.4 influence to mice with viral myocarditis myocardial cell infiltration and degree of necrosis
Test the 15th day, mouse is all dissected.Take out heart, put in the formalin solution, under inverted phase contrast microscope, observe after doing pathological section, each sample is observed 5 high power fields, and record soaks into and and downright bad situation.Each visual field, pathology 0 ~ 25% are designated as 1,25% ~ 50% and are designated as 2,50% ~ 75% and are designated as 3,75% ~ 100% and are designated as 4.
The result shows that two dose groups of medicine of the present invention all can significantly improve by coxsackie B
3Virus (CVB
3) infect the heart change situation of the mice with viral myocarditis cause.
Table 4 medicine of the present invention is to the influence of mice with viral myocarditis myocardial cell infiltration and degree of necrosis
| Group | Soak into | Downright bad |
| The normal control group | 0 | 0 |
| The virus control group | 1.9±0.61 | 2.2±0.43 |
| High dosage administration group | 0.7±0.55** | 1.3±0.58** |
| Low dosage administration group | 1.1±0.72** | 1.6±0.41** |
Annotate: the administration group compares * * P < 0.01 with the virus group.
Claims (9)
1. one kind prepares the method for Cyclosiversioside F through the microbial transformation Radix Astragali total saponins, it is characterized in that it comprises step:
Microbial strains is processed bacteria suspension or spore suspension; Be inoculated in the seed culture medium, 28 ℃, 220 rpm are cultivated 24 ~ 48 h and are promptly got seed liquor, seed liquor are inoculated in the fermention medium again; 28 ℃, 220 rpm are cultivated 24 ~ 48 h; Drop into Radix Astragali total saponins, the same terms transforms 48 ~ 96 h down, gets conversion fluid; Conversion fluid obtains purity astragaloside through organic solvent extraction and macroporous resin separation and purification.
2. by the described method of claim 1; It is characterized in that; Described Radix Astragali total saponins, its composition comprise following all or part of Radix Astragali saponin monomer: astragaloside I, II, VI, VII, isoastragaloside I, II; The acetylastragaloside I, agroastragaloside III, IV and/or Cycloglobiceposide A.
3. by the described method of claim 1, it is characterized in that described mikrobe is selected from bacterium, mould or yeast.
4. by the described method of claim 1, it is characterized in that described mikrobe is absidia corymbifera (Absidia corymbifera).
5. by the described method of claim 1, it is characterized in that described microbial transformation Cyclosiversioside F is through ethanoyl and glycosyl in the microbial hydrolytic Radix Astragali total saponins that contains deacetylase and Glycosylase, improve Astragaloside content.
6. by the described method of claim 1; It is characterized in that described conversion fluid is through organic solvent extraction and macroporous resin separation and purification Cyclosiversioside F; Or elder generation adopts alcohol immersion; Use n-butanol extraction again, gained medicinal extract adopts the separation and purification of D101 macroporous resin again, behind ethyl acetate extraction, obtains purity astragaloside.
7. astragaloside injection is characterized in that, Cyclosiversioside F 1 g, ethanol 200 mL, Ucar 35 200 mL, glucose 100 g that made by claim 1, supplies water for injection to 1000 m and processes L.
8. the purposes of the astragaloside injection of claim 7 in preparation treatment cardiovascular disorder, cerebrovascular disease, anticancer, antiviral or diabetes medicament.
9. by the described purposes of claim 8, it is characterized in that described cardiovascular disorder is a viral myocarditis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010615265.4A CN102559828B (en) | 2010-12-30 | 2010-12-30 | Method for preparing astragaloside IV by converting total saponins of astragalus by microorganisms |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010615265.4A CN102559828B (en) | 2010-12-30 | 2010-12-30 | Method for preparing astragaloside IV by converting total saponins of astragalus by microorganisms |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102559828A true CN102559828A (en) | 2012-07-11 |
| CN102559828B CN102559828B (en) | 2014-06-11 |
Family
ID=46406433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010615265.4A Expired - Fee Related CN102559828B (en) | 2010-12-30 | 2010-12-30 | Method for preparing astragaloside IV by converting total saponins of astragalus by microorganisms |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102559828B (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103305572A (en) * | 2013-05-31 | 2013-09-18 | 西昌丹阳生物科技有限责任公司 | Method for producing baohuoside I through herba epimdii |
| CN104711312A (en) * | 2015-03-15 | 2015-06-17 | 北京化工大学 | Method for preparing astragaloside from trichoderma viride |
| CN105481934A (en) * | 2015-12-02 | 2016-04-13 | 上海景峰制药有限公司 | Astragaloside bulk drug and preparation method thereof |
| CN105541954A (en) * | 2015-12-02 | 2016-05-04 | 上海景峰制药有限公司 | Radix astragali extract with high purity astragaloside |
| CN105861614A (en) * | 2016-05-12 | 2016-08-17 | 中国农业科学院农业资源与农业区划研究所 | Application of aspergillus niger in preparation of astragaloside |
| CN111705097A (en) * | 2020-06-30 | 2020-09-25 | 山东康裕生物科技有限公司 | Purification process of radix astragali for animal feed additive |
| CN112057499A (en) * | 2020-08-20 | 2020-12-11 | 武汉自在生物科技有限公司 | Preparation method of antitumor drug |
| CN114748490A (en) * | 2022-04-24 | 2022-07-15 | 南方科技大学 | Pharmaceutical composition for treating premature ovarian failure, application and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1923211A (en) * | 2005-09-02 | 2007-03-07 | 天津药物研究院 | Astragaloside injection and preparation thereof |
| CN101130802A (en) * | 2007-07-30 | 2008-02-27 | 金凤燮 | Method for preparing astragaloside iv by enzymic hydrolysis for astragalus saponin glycosyl |
-
2010
- 2010-12-30 CN CN201010615265.4A patent/CN102559828B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1923211A (en) * | 2005-09-02 | 2007-03-07 | 天津药物研究院 | Astragaloside injection and preparation thereof |
| CN101130802A (en) * | 2007-07-30 | 2008-02-27 | 金凤燮 | Method for preparing astragaloside iv by enzymic hydrolysis for astragalus saponin glycosyl |
Non-Patent Citations (2)
| Title |
|---|
| 石海莲，吴大正，胡之璧: "黄芪皂苷甲的研究进展", 《中国药学杂志》 * |
| 高越，李翔，朱臻宇，柴逸峰: "大孔树脂吸附法对黄芪皂苷Ⅳ富集纯化工艺的研究", 《第二军医大学学报》 * |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103305572A (en) * | 2013-05-31 | 2013-09-18 | 西昌丹阳生物科技有限责任公司 | Method for producing baohuoside I through herba epimdii |
| CN103305572B (en) * | 2013-05-31 | 2014-12-24 | 西昌丹阳生物科技有限责任公司 | Method for producing baohuoside I through herba epimdii |
| CN104711312A (en) * | 2015-03-15 | 2015-06-17 | 北京化工大学 | Method for preparing astragaloside from trichoderma viride |
| CN104711312B (en) * | 2015-03-15 | 2018-02-23 | 北京化工大学 | The method that Astragaloside IV is prepared using Trichoderma viride |
| CN105481934A (en) * | 2015-12-02 | 2016-04-13 | 上海景峰制药有限公司 | Astragaloside bulk drug and preparation method thereof |
| CN105541954A (en) * | 2015-12-02 | 2016-05-04 | 上海景峰制药有限公司 | Radix astragali extract with high purity astragaloside |
| CN105861614A (en) * | 2016-05-12 | 2016-08-17 | 中国农业科学院农业资源与农业区划研究所 | Application of aspergillus niger in preparation of astragaloside |
| CN105861614B (en) * | 2016-05-12 | 2020-08-04 | 中国农业科学院农业资源与农业区划研究所 | Application of aspergillus niger in preparation of astragaloside |
| CN111705097A (en) * | 2020-06-30 | 2020-09-25 | 山东康裕生物科技有限公司 | Purification process of radix astragali for animal feed additive |
| CN112057499A (en) * | 2020-08-20 | 2020-12-11 | 武汉自在生物科技有限公司 | Preparation method of antitumor drug |
| CN114748490A (en) * | 2022-04-24 | 2022-07-15 | 南方科技大学 | Pharmaceutical composition for treating premature ovarian failure, application and preparation method thereof |
| CN114748490B (en) * | 2022-04-24 | 2023-12-12 | 南方科技大学 | Pharmaceutical composition for treating premature ovarian failure, application and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102559828B (en) | 2014-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102559828B (en) | Method for preparing astragaloside IV by converting total saponins of astragalus by microorganisms | |
| CN1321186C (en) | Chinese traditional medicine containing glycosides transformed by ferment of microbe, and method for producing relevant aglycone preparation | |
| CN105755090A (en) | Method for acquiring secondary metabolites including panax japonicus saponins and the like with large-scale culture and bioconversion technology for panax japonicus cells | |
| CN106085868A (en) | One strain produces aspergillosis and the application thereof of HIV (human immunodeficiency virus)-resistant activity material | |
| CN101067146A (en) | Biological extraction process of main chemical components in licorice | |
| CN104357332B (en) | Aspergillus niger JH-2 and application to biotransformation and synthesis of asiatic acid | |
| CN106086147A (en) | Fungal elicitor is utilized to induce the method extracting betulic acid from Inonqqus obliquus | |
| CN104726347B (en) | One plant of fox excrement mould fungal bacterial strain and the method for preparing left-handed 7 hydroxyl butylphenyl phthaleine using the bacterial strain | |
| CN103146592A (en) | Microzyme converting ginsenoside Rb1 to generate Rd and application thereof | |
| CN104087645B (en) | A kind of solid fermentation flower of Panax ginseng and preparation method | |
| CN103815279B (en) | Red yeast rice rich in coenzyme Q10 and preparation method thereof | |
| CN103193854B (en) | The separation and purification of betulin and the biological and chemical method for transformation of betulinic acid | |
| CN107189949A (en) | Rhizopus oryzae LJH3 and the application in bioconversion Sophoricoside prepares genistein | |
| CN106119333A (en) | A kind of method utilizing fatty acid-induced to extract betulic acid from Inonqqus obliquus | |
| CN101412743B (en) | Preparation of 2 alpha-hydroxy-substituted white birch keto acid | |
| CN108640956A (en) | A method of preparing flavonoid glycoside from tea seed | |
| CN107974412A (en) | A kind of penicillium roqueforti for being used to prepare antiinflammatory active compound peniroquesine A and its application | |
| CN105998222B (en) | The composition and its preparation method and application of probiotics fermention unprocessed Radix Aconiti Lateralis | |
| CN106635840B (en) | A kind of Aspergillus niger strain and its fermented Chinese gall herb and tea leaves that ferment generate the preparation method and application of new component | |
| CN116103161A (en) | Plant endophytic fungus for producing eupatorium and application thereof | |
| Chen et al. | Biotransformation of saponins to astragaloside IV from Radix Astragali by immobilized Aspergillus niger | |
| CN105803015A (en) | Method for converting dicentrine into (4S,6aR)-4-hydroxyl dicentrine through Clonostachys sp. Fermentation | |
| CN102093187A (en) | Polyketone compounds and application thereof | |
| CN105543320B (en) | A method of promote reducing power regeneration to improve microorganism and is hydroxylated DHEA transformation efficiency | |
| CN104611400A (en) | Method of utilizing coenzyme regeneration and resin in-situ extraction to promote hydroxylation of DHEA by Colletotrichum lini ST-1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140611 Termination date: 20161230 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |